Nav: Home

Three vaccine approaches protect monkeys against Zika infection

August 04, 2016

WHAT:

Three different investigational Zika virus vaccine platforms--an inactivated virus vaccine, a DNA-based vaccine, and an adenovirus vector-based vaccine--protected against infection, induced immune responses, and produced no adverse side effects when tested in rhesus macaques challenged with the Zika virus, according to findings appearing August 4 in the journal Science. The results suggest that each of the three approaches holds promise for designing an effective Zika vaccine, according to the authors.

Researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, first tested the inactivated Zika virus vaccine in 16 rhesus macaques, with eight receiving the experimental vaccine and eight receiving a placebo injection. Within two weeks after the initial injection, all vaccinated animals developed neutralizing antibodies as well as antibodies specific to the viral envelope protein, a key vaccine target on the Zika virus. A second dose was given four weeks later, which substantially boosted antibody levels. The monkeys were then challenged with Zika virus; following exposure, the vaccinated animals had no detectable virus and showed no other evidence of infection, while the group that received the placebo injection developed high levels of virus replication in the blood and other tissues for six to seven days.

In another experiment, the researchers administered two doses of an experimental DNA vaccine, one dose of an experimental adenovirus vector vaccine, or a placebo injection to three groups of four monkeys each. The group that received the DNA vaccine received a booster shot four weeks after the initial vaccination. Minimal levels of antibodies were detected after the first injection. However, after the second injection, researchers detected Zika-specific neutralizing antibodies in the animals. The adenovirus vector-based vaccine induced Zika-specific neutralizing antibodies two weeks after the single injection. Monkeys were exposed to Zika virus four weeks after the final vaccination, and both the DNA and adenovirus vector vaccine provided complete protection against infection. These encouraging findings suggest a path forward for clinical development of Zika vaccines in humans, according to the researchers.
-end-
ARTICLE:

P Abbink et al. Protective efficacy of multiple platforms against Zika virus challenge in rhesus monkeys. Science DOI: 10.1126/science.aah6157 (2016).

WHO:

NIAID Director Anthony S. Fauci, M.D. is available for comment.

CONTACT:

To schedule interviews, please contact Emily Mullin, (301) 402-1663, emily.mullin@nih.gov.


NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

NIH/National Institute of Allergy and Infectious Diseases

Related Antibodies Articles:

Researchers discover first human antibodies that work against all ebolaviruses
After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses.
New method enables creation of better therapeutic antibodies
Researchers from the University of Maryland and Rockefeller University have refined a method to modify an antibody's sugar group structure, which plays a large role in determining an antibody's ability to activate the immune response.
Antibodies as 'messengers' in the nervous system
Antibodies are able to activate human nerve cells within milliseconds and hence modify their function -- that is the surprising conclusion of a study carried out at Human Biology at the Technical University of Munich (TUM).
Turning therapeutic antibodies inside-out to fight cancer
Researchers at the University of California, Riverside have camels and llamas to thank for their development of a new cancer treatment that is highly selective in blocking the action of faulty matrix metalloproteinases (MMPs).
Zika antibodies from infected patient thwart infection in mice
Researchers have identified neutralizing antibodies against Zika virus from an infected patient that fully protected mice from infection, adding to the current arsenal of antibodies in development for much needed antiviral therapies and vaccines.
A review on the therapeutic antibodies for spinal cord injury
Spinal cord injury (SCI) causes long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities.
Training human antibodies to protect against HIV
During HIV infection, the virus mutates too rapidly for the immune system to combat, but some people produce antibodies that can recognize the virus even two years after infection.
How antiviral antibodies become part of immune memory
Emory scientists probe activated B cells, important for forming immune memory, during flu vaccination and infection and Ebola infection in humans.
Mouse antibodies pinpoint Zika's weak spots
Antibodies that specifically protect against Zika infection have been identified in mice, report Washington University School of Medicine in St.
Antibodies identified that thwart Zika virus infection
Scientists at Washington University School of Medicine in St. Louis have identified antibodies capable of protecting against Zika virus infection, a significant step toward developing a vaccine, better diagnostic tests and possibly new antibody-based therapies.

Related Antibodies Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...